Total Funding
91
70
Total FundingGrant raised
Growth Score
18 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
91548
N-lorem foundation focuses on creating individual treatment for patients with ultra-rare diseases caused by genetic mutations.
Stanley Crooke: Founder & CEOPast Role: Ionis Pharmaceuticals, Chief Executive Officer
About the Company
N-Lorem Foundation uses antisense technology to create individualized treatments for patients with nano-rare diseases. Antisense medicines, also known as antisense oligonucleotides or ASOs, are intended to precisely connect with RNA, preventing the process of generating a protein that causes sickness. This disrupts the course of diseases, from the
most uncommon to those that affect millions of people. For nano-rare patients who are amenable to the company's technology, the n-Lorem Foundation provides the infrastructure, resources, and access necessary for them to receive experimental Antisense oligonucleotides (ASOs) without charge.
